Covidien hernia mesh litigation remains active nationwide. On August 4, 2026, a federal jury returned an $88 million verdict in the first Covidien bellwether trial involving Symbotex mesh. The court has now scheduled a second Symbotex bellwether trial for January 11, 2027.
Doyle APC is a California-based product liability firm representing Covidien hernia mesh clients from across the United States. We currently represent approximately 60 people pursuing Covidien mesh claims and continue to evaluate new cases involving serious complications that required revision or removal surgery.
No global Covidien hernia mesh settlement has been announced. Approximately 10,500 U.S. plaintiffs were pursuing Covidien hernia mesh claims as of August 2026, and the federal litigation is moving into a new round of bellwether trials. Our current hernia mesh practice is focused on Covidien polyester-based products, including Parietex, Symbotex, and ProGrip, where complications have required at least one revision or removal surgery.
Had Covidien hernia mesh removed or revised? Contact our attorneys for a free case review. If you do not know which mesh was implanted, we can review your surgical records to identify the product.
Status of the Covidien Hernia Mesh MDL (No. 3029)
Last Updated: September 16, 2026
Federal and State Court Cases
Covidien hernia mesh lawsuits continue in federal and state courts. As of September 1, 2026, 2,453 cases were pending in federal MDL No. 3029 before U.S. District Judge Patti B. Saris in Massachusetts. Medtronic reported to the SEC that, as of August 5, 2026, it and its subsidiaries faced claims from approximately 10,500 U.S. plaintiffs, including roughly 7,450 plaintiffs in coordinated Massachusetts state-court litigation and approximately 500 plaintiffs in Minnesota state court.
The federal MDL has progressed through extensive discovery and has now entered an active trial phase. The first federal bellwether resulted in an $88 million plaintiff verdict in August 2026. Medtronic has stated that it intends to challenge that verdict through post-trial proceedings and, if necessary, appeal. Meanwhile, the court has scheduled the second bellwether for January 11, 2027.
Key Case Developments
First Bellwether Trial: $88 Million Plaintiff Verdict (August 4, 2026)
A federal jury in Boston returned an $88 million verdict against Covidien in Patterson v. Covidien, Inc., No. 22-cv-10153-PBS, the first Covidien hernia mesh case in the country to reach a jury. The award was $77 million to the plaintiff and $11 million to his wife on her loss of consortium claim. The jury found that Covidien failed to give adequate warning of the dangers posed by its Symbotex mesh.
The plaintiff, a 61 year old Alabama man implanted with Symbotex during a 2017 hernia repair, proved that the mesh’s collagen layer resorbed prematurely, leading to severe adhesions, a bowel obstruction, and a small bowel resection that removed roughly three inches of intestine. He described continuing problems since that surgery, including a non healing wound, recurrent hernias, and periodic infections.
The jury declined to award punitive damages and did not find fraud. The full $88 million is compensatory, meaning it reflects what the jury concluded the injuries themselves were worth.
Covidien’s own scientists testified that Symbotex’s protective collagen barrier begins deteriorating within hours and fully breaks down within about seven days, while sales representatives were trained to tell surgeons the barrier lasted up to 30 days. The case was not simply that the device was defective, but that the implanting surgeon was never told how long the barrier would actually protect his patient’s bowel. The jury accepted that failure to warn theory. Medtronic has said it will challenge the verdict through post-trial motions and appeal.
The verdict follows Judge Saris’s June 2, 2026 ruling denying the bulk of Covidien’s motion for summary judgment, which cleared nearly all of the Patterson claims for trial. The court found that a reasonable jury could conclude that Covidien knowingly misrepresented how long Symbotex’s collagen barrier lasts and the risk that posed to patients. Because those theories apply broadly across the litigation, both the ruling and the verdict speak directly to the thousands of pending Covidien cases.
Additional bellwether proceedings are now moving forward. The next trial, Stephen v. Covidien, Inc., involves another Symbotex implant and is scheduled to begin on January 11, 2027.
Second Bellwether Trial: Stephen v. Covidien Set for January 11, 2027
On August 25, 2026, Judge Patti B. Saris entered an order scheduling the second federal Covidien hernia mesh bellwether trial for January 11, 2027. The case is Stephen v. Covidien, Inc., No. 22-cv-11590-PBS, brought by Mississippi resident Regina Stephen.
According to Stephen’s allegations, she received a Covidien Symbotex mesh during a ventral hernia repair in 2017. She later developed significant small-bowel adhesions and underwent additional surgery in July 2020. Her lawsuit alleges that the mesh’s collagen coating resorbed prematurely, exposing the underlying mesh and contributing to adhesions, chronic inflammation, pain, bowel problems, infections, and the need for further surgery.
The Stephen case is important because it puts Symbotex before a second federal jury only months after the $88 million Patterson verdict. Although every case involves different medical facts and potentially different state law, both cases involve allegations concerning Symbotex’s absorbable collagen barrier and injuries associated with adhesions after implantation.
The court has set a December 1, 2026 deadline for the parties’ pretrial memorandum and a December 10 final pretrial conference. Unless the case is resolved or the schedule changes, jury selection and trial are scheduled to begin January 11.
What the $88 Million Verdict Means for Pending Cases
A single verdict does not resolve anyone else’s case. The Patterson verdict is also subject to post-trial challenge and possible appeal. But it represents the first time a federal jury has evaluated the parties’ evidence in the Covidien MDL, and the litigation is now moving directly toward another Symbotex trial.
In Patterson, the jury found that Covidien failed to adequately warn about risks associated with Symbotex and awarded $88 million in compensatory damages. The January 2027 Stephen trial will give a second jury an opportunity to evaluate allegations involving the same Symbotex product and similar concerns about its collagen barrier.
No global Covidien settlement has been announced. With additional bellwether proceedings scheduled and thousands of claims still pending, the litigation remains active rather than being in a settlement-administration phase.
For patients, the practical point is simple. Filing deadlines continue to run regardless of the bellwether schedule. Anyone who has undergone revision or removal surgery because of complications involving Covidien mesh should have the applicable statute of limitations evaluated promptly rather than waiting to see whether the litigation eventually settles.
Injuries That Lead to Revision Surgery
Patients with defective hernia mesh often report painful and life-altering complications. These problems can emerge months or even years after surgery, making it difficult for patients and doctors to connect the symptoms to the implant.
Our firm focuses on cases where patients have experienced severe complications such as:
- Chronic Pain and Foreign Body Sensation: Patients can experience persistent, debilitating pain in the abdomen, groin, or leg, often described as a constant pulling, burning, stiffness, or the sensation of a hard, foreign object inside the body. This can happen when the mesh shrinks and hardens, pulling on nerves and tissue.
- Adhesions, Bowel Obstruction, and Perforation: The mesh material can incite a severe inflammatory response, causing dense scar tissue (adhesions) to form that binds the mesh to the intestines or other organs. The result can be a life-threatening bowel obstruction, or erosion of the mesh through the intestinal wall.
- Mesh Migration and Failure: Defective mesh can shrink, unravel, or break apart inside the body. Fragments can then migrate from the original implant site, potentially damaging other organs or tissues. This structural failure often leads to a recurrence of the original hernia.
- Recurring and Chronic Infections: The porous nature of hernia mesh, particularly degrading polyester, can harbor bacteria and lead to chronic infections that do not respond to antibiotics. In severe cases, this can lead to sepsis, abscess formation, or emergency surgery to remove the infected device.
- Nerve Damage and Testicular Complications: In inguinal hernia repairs, mesh can entrap or damage nerves in the groin, causing chronic pain or numbness. In men, mesh has been shown to migrate into the spermatic cord, sometimes requiring surgical removal of a testicle (orchiectomy).
If you have experienced these serious complications from Covidien hernia mesh and have required revision surgery, contact our attorneys for a free case evaluation.
Why Parietex Mesh Fails
Covidien introduced Parietex surgical mesh for ventral hernia repair in 1999. The company chose polyester fabric instead of polypropylene, used in most other hernia meshes. Parietex and Symbotex received FDA clearance through the 510(k) process as Class II devices, Symbotex in 2013, meaning Covidien avoided human clinical trials before marketing the products by claiming they were “substantially equivalent” to existing devices.
Unlike polypropylene, polyester is not chemically inert in the body. It can shrink significantly after implantation, its fibers can unravel and stiffen until the mesh turns rigid, and the material degrades faster than expected, which can cause the repair itself to fail. Plaintiffs allege polyester mesh causes greater degradation, higher rates of chronic infection, excessive shrinkage, and premature breakdown of protective collagen barriers. Covidien’s Parietex products feature anti-adhesion coatings, but these do not work as intended. The collagen barrier absorbs too quickly, exposing the polyester underneath and allowing it to adhere to internal organs. That is the theory the Patterson jury accepted when it found that Covidien failed to warn surgeons and awarded $88 million.
Products at Issue
Covidien hernia mesh products named in litigation include:
- Parietex Composite (PCO) Mesh
- Parietex Composite Mono PM Mesh
- Parietex Composite PCO-OS (Open Skirt) Mesh
- Parietex Composite PCO-OB Mesh
- Parietex Composite Ventral Patch
- Parietex Composite Parastomal Mesh
- Parietex Optimized Composite Mesh
- Parietex Optimized Open Skirt Mesh
- Parietex ProGrip Self-Fixating Mesh
- Parietex ProGrip Laparoscopic
- Parietex Lightweight Monofilament Mesh
- Parietex Monofilament Polyester Mesh
- Parietex Plug and Patch System
- Symbotex Composite Mesh (subject of the first two federal bellwether trials)
- Parietene DS Composite Mesh (polypropylene)
- Parietene Polypropylene Mesh
- Parietene ProGrip Mesh
- Surgi Pro and SurgiPro Plug & Patch
- Dextile Anatomical Mesh
Pursuing Compensation
If you required revision surgery due to complications from Covidien hernia mesh, you may be entitled to compensation. These are not routine surgical outcomes. Covidien failed to adequately warn doctors and patients about known risks, including shrinkage, degradation, migration, and erosion.
Compensation can cover medical expenses for revision surgeries and the pain and suffering caused by the device. A spouse may also have a separate claim for loss of consortium, as the plaintiff’s wife did in Patterson.
Who Qualifies
Doyle APC is currently evaluating Covidien hernia mesh cases nationwide. We primarily consider cases involving a Covidien polyester mesh product, including Parietex, Symbotex, or ProGrip, where the patient experienced a serious complication and underwent at least one revision or mesh-removal surgery.
Complications in the cases we evaluate commonly include adhesions, bowel obstruction, recurrent hernia, chronic infection, mesh contraction or migration, severe chronic pain, erosion into surrounding tissue, or other problems that required additional surgery.
You do not need to know the exact name of your mesh before contacting us. The manufacturer and product are often identified in the operative report or implant record from the original hernia surgery. We can review those records and help determine whether a Covidien product was used.
Why Choose Doyle APC
- Currently Representing Approximately 60 Covidien Hernia Mesh Clients: Our firm already represents approximately 60 people pursuing claims involving Covidien hernia mesh. We are actively following MDL 3029 and the related bellwether proceedings as those cases move toward additional trials.
- Nationwide Covidien Representation: Although Doyle APC is based in California, our Covidien MDL practice is nationwide. We represent clients from throughout the United States in this litigation, subject to the filing and jurisdictional requirements applicable to each individual case.
- Over 28 Years of Product Liability Experience: Our practice focuses on holding manufacturers accountable for defective products, ranging from consumer goods and pharmaceuticals to medical implants, such as hernia mesh.
- Boutique Representation, Deep Involvement: We deliberately maintain a focused product-liability practice and personally evaluate the medical and product history of the cases we accept.
- Proven Track Record in Complex Cases: Our attorneys have led major class actions and complex litigation across the country, including high-stakes cases against prominent companies such as Apple, Honda, and Amazon, as well as leading device manufacturers. We’ve secured hundreds of millions of dollars for clients injured by defective products.
- Contingency Representation: You pay nothing unless we recover compensation for you.
Frequently Asked Questions
Why only Covidien cases and not Bard?
Bard’s parent company, BD, announced a confidential settlement framework in October 2024 intended to resolve the vast majority of its existing hernia mesh litigation. Covidien’s litigation is at a different stage: no global settlement has been announced, the first federal bellwether reached a jury in August 2026, and the next bellwether is scheduled for January 2027. We focus our resources where the litigation remains active.
What if I don’t know which mesh I have?
This is a very common situation. Most patients are not told the specific brand or model of the mesh used in their surgery. The operative report from your surgery will usually name the manufacturer and model, and many hospitals now make those records available through a patient portal. We can also obtain the records for you to identify the exact product. Our current hernia mesh practice is focused on qualifying Covidien products, including Parietex, Symbotex, and ProGrip.
What is the filing deadline for a Covidien hernia mesh lawsuit?
The filing deadline depends on the law of the state applicable to your individual claim and can vary substantially from state to state. Hernia mesh cases can be especially complicated because the original implant may have occurred years before the patient developed complications or learned that the mesh could be involved.
For example, California generally applies a two-year limitations period to personal-injury product liability claims, subject to rules governing when the claim accrued or reasonably should have been discovered. Other states may provide shorter deadlines. The federal MDL does not create a new nationwide statute of limitations, so the deadline applicable to an individual claim should be evaluated promptly.
What is a bellwether trial, and does it decide my case?
A bellwether trial is a test case chosen from a large group of similar lawsuits, such as those in an MDL. The result binds only the parties to that case, but it shows both sides how a jury responds to the core evidence, and it heavily influences settlement negotiations for the thousands of remaining claims. The first Covidien bellwether trial, Patterson v. Covidien, began on July 13, 2026 and ended on August 4, 2026 with an $88 million verdict for the plaintiff. That result does not decide another plaintiff’s case and does not entitle anyone else to a similar recovery. A second Symbotex bellwether, Stephen v. Covidien, is scheduled for January 11, 2027.
Does the $88 million verdict mean my case is worth $88 million?
No. That figure reflects one man’s injuries, one family’s losses, and the evidence presented in one trial under Alabama law. Awards in individual mesh cases vary enormously with the severity of injury, the number of revision surgeries, the medical documentation, and the state whose law applies. Most claims in litigation of this size resolve through negotiated settlement rather than trial, at values well below a headline verdict. What the verdict changes is the negotiating environment, not the value of any particular claim.
Has Covidien settled the hernia mesh lawsuits?
No global settlement of the Covidien hernia mesh litigation has been announced as of September 2026. The first federal bellwether trial resulted in an $88 million plaintiff verdict on August 4, 2026, which Medtronic has said it intends to challenge. A second Symbotex bellwether trial is scheduled for January 11, 2027.
Bellwether verdicts do not determine the outcome or value of other plaintiffs’ cases. They provide both sides with information about how juries respond to evidence that may recur across the litigation and can affect future litigation and settlement decisions.
Do I have to live in California to hire Doyle APC for a Covidien mesh case?
No. Our California product liability practice handles individual Covidien hernia mesh claims from across the United States in connection with the federal MDL litigation. Whether we can accept a particular case depends on the medical facts, the product involved, the applicable state law, and the filing deadline.
Another firm turned my case down. Why would you be different?
Many large, national law firms that handle mass torts operate on a volume-based model. They may decline or drop cases that require more intensive investigation or have complex medical facts. As a boutique product liability firm, we specialize in exactly these types of cases. We focus on serious product-injury cases and individually evaluate the medical and product history of each potential Covidien claim.
What does it cost to hire your firm?
We represent all clients on a contingency fee basis. This means you pay no upfront costs or out-of-pocket fees. Our firm advances all costs of litigation. We only receive a fee if we successfully recover compensation for you. If there is no recovery, you owe us nothing.
Free Covidien Hernia Mesh Case Review
If you received Covidien Parietex, Symbotex, or ProGrip hernia mesh and later required revision or removal surgery, Doyle APC can review your case at no charge. We currently represent approximately 60 Covidien hernia mesh clients and are accepting qualifying cases from across the United States.
Do not worry if you do not know the manufacturer or exact model of your mesh. We can review the operative report and implant records from your original surgery to determine what product was used.
Filing deadlines vary by state and continue to run while the bellwether litigation proceeds. The January 2027 trial does not extend the deadline for filing an individual claim. Contact us today for a free, confidential evaluation. There is no cost or obligation, and you pay no attorney’s fee unless we obtain a recovery for you.
GET A FREE COVIDIEN HERNIA MESH CASE REVIEW